United States v. 39 Bags, More or Less, "Elip Tablets"

BRUCHHAUSEN, District Judge. The libelant instituted this action to condemn a quantity of drugs and advertising material, upon the ground that the drugs were misbranded or mislabeled, in violation of the Federal Food, Drug and Cosmetic Act, 21 U.S.C.A. § 301 et seq. “The purpose of the law is to protect the public, the vast multitude which includes the ignorant, the unthinking, and the credulous who, when making a purchase, do not stop to analyze. It was enacted to máke self-medication safer and more effective, and to require that *649 drugs moving in interstate commerce be properly labeled so that their use as prescribed may not be dangerous to the health of the user.” United States v. 62 Packages, etc., D.C., 48 F.Supp. 878, 887, affirmed 7 Cir., 142 F.2d 107, cer-tiorari denied Raladom v. U. S., 323 U. S. 731, 65 S.Ct. 68, 89 L.Ed. 587. The term “labeling” applies to the matter printed or written upon the article itself, and upon the containers or wrappers accompanying it. 21 U.S. C.A. § 321 (m). A drug is deemed misbranded “if its labeling is false or misleading in any particular” also if the labeling fails to include adequate warnings as to its use. 21 U.S.C.A. § 352 (a, f). It is not disputed that the claimant Ira Lichtenstein, doing business as Baldwin Laboratories, conceived the formula for the drugs or tablets in question; that the formula consisted of a mixture of flowers of sulphur, rhubarb root and cream of tartar; that the said claimant engaged Jabert Pharmacal Company, Inc., to manufacture the tablets, and that the said claimant contracted with the claimant Elip Distributing Corporation to market them, including packaging and advertising. The contention is that in the process of marketing the tablets, the claimants deceived the public in asserting that the tablets would relieve the ailment, known as “Piles”. It is interesting to note that the manufacturer made no such assertion. Its label on the gross shipment to the distributors made no mention of such ailment but designated the tablets as “laxatives”. The distributors did not use that label but prepared a different label, inserted it in each package or vial of 12 tablets, reading, in part: “Elip Tablets — A palliative treatment for discomfort and itching of rectal irritation caused by piles.” The counter display cards contained the statement: “An internal preparation for the relief of piles. Price $2. Elip Reg. U.S.Pat.Off.” A neon sign in the window of Baldwin Laboratories read: “Elip for Piles”. During the trial, the claimants stipulated that the labeling should contain a warning against using the tablets for bleeding piles. “Elip”, the designation used by the claimants in promoting the product is “pile” spelled backwards. The three medical experts produced by the Government, expert proctologists, testified that Elip tablets are laxatives and not particularly mild and that the only complete cure for piles is surgery. The claimant Lichtenstein, a pharmacist, admitted that surgery was the only known complete cure for piles, but denied that Elip was held out as a cure. He said that he conceived the tablet as a mild laxative softening the digested matter passing over the pile area, and containing an astringent for washing the affected area. Either he or his medical witness also asserted the qualities of the tablets were such that the laxative did not operate until it reached the large intestine, thus guaranteeing a complete movement and that there were certain germ killing qualities in the drug. Apparently no certain medication has been discovered to date which will cure piles nor are the specific causes known. They are known as hemorrhoids in medical terminology, and consist of swollen veins in the lower end of the large intestine, or anus, brought on by such causes as constipation, infection, over-straining, heredity, childbirth, tension, worry and diet. If they protrude, they are known as external as distinguished from internal hemorrhoids, and when dilated they are very painful. Very often they bleed. Temporary relief comes with the lessening of congestion. Sometimes, as with common colds, piles cure themselves. A controlled experiment was conducted at Bellevue Hospital by Dr. Max P. Cow-ett, a distinguished proctologist. He testified that twenty-eight patients, interspersed between hospital and clinic *650 patients, were treated with Elip tablets for a period of almost four months. An additional twenty were given placebos in the form of milk sugar tablets. The results were uncomplimentary to Elip. Several 'of those using the tablets grew worse, or complained of abdominal cramps, with increased bowel movements, and tenesmus, or bowel frustration. The experiment with some patients had to be discontinued. Several required either surgery or sclerosing. None of the patients on either the Elip or the placebo benefited during the treatment. Various newspaper and periodical advertisements were submitted in evidence as proof of the intent of the labels, although not as evidence of the labeling itself. Such evidence is competent. Colgrove v. United States, 9 Cir., 176 F.2d 614, certiorari denied 338 U.S. 911, 70 S.Ct. 349, 94 L.Ed. 561; Research Laboratories v. United States, 9 Cir., 167 F.2d 410, certiorari denied 335 U.S. 843, 69 S.Ct. 65, 93 L.Ed. 393; United States v. Vitamin Industries, Inc., D.C.Neb., 130 F.Supp. 755. In newspaper advertising and throwaways, the claimant made claims for the tablets such as: “Piles checked in 72 hours with tablets * * * in 72 hours the bleeding stopped * * * Elip brings sure relief from pile misery * * * the only internal pile remedy.” It is plain that the claimants entered into a campaign of “bait advertising”. A product manufactured as a laxative, without any changes by the promoters, is held out to the unsuspecting public as a remedy for another condition, piles. The recklessness of the claimants and their utter disregard of those whom they catered to is evidenced by their admission that the tablets could not aid anyone afflicted with bleeding piles. That the element of large profit was not absent from this enterprise is inferable. The tablets cost the claimants about one-tenth of a cent each and were sold by the claimants at $2 per package of 12 tablets. It is fairly apparent that if the claimants had informed the purchasers that the product was nothing more than a laxative, they would have been obliged to compete with the large number of producers of that article and would not have interested the pile sufferers. A decree is directed for the relief demanded in the libel.